The Zurich-based biopharmaceutical company, Numab Therapeutics, is focused on oncology and is using its proprietary MATCH™ technology platform to create multi-specific antibodies for novel therapeutic strategies in cancer immunotherapy. Their lead product targets 4-1BB, PD-L1, and Human Serum Albumin simultaneously, aiming to achieve potent anti-tumor immunity while maintaining a favorable safety profile. By prioritizing high-quality standards throughout the drug design process, Numab Therapeutics aims to improve patient outcomes.